our approach
badge

Our approach is guided by our vision to advance patient care, by empowering the healthcare community with effective precision diagnostics.

It’s simple. It’s science. After platelet activation, FcyRIIa on the surface clusters and cross-links. Cross-linking of FcyRIIa leads to downstream signaling and amplification of platelet activation. As a result, while platelets from healthy young people carry approximately 4,000 molecules of FcyRIIa1, those from patients with cardiovascular disease can carry more than 10,000 molecules2.

normal platelet
Normal Platelet
approach red arrow
activated platelet
Activated Platelet
the test
badge

The test uses flow cytometry to quantify the number of FcyRIIa molecules per platelet.

information

Our test is not yet commercially available. It is only available to participants of Prolocor’s clinical studies.

Flow cytometry is a procedure in which blood is added to a tube that contains an antibody to FcyRIIa. The antibody is tagged with a fluorochrome (a chemical that emits light). A laser shines on the sample, and fluorescence is emitted from FcyRIIa. This can be used to quantify the amount of FcyRIIa in 10,000 platelets per minute.

A pilot prospective study showed a significant predictive value of our test in nearly 200 patients with a prior heart attack2-3.

pulsating arrowpulsating arrow
illustration
A 4-fold greater risk for a recurrent cardiovascular event in patients with HIGH FcγRIIa.
pulsating arrowpulsating arrowwhite arrow
illustration
A 4-fold greater risk for a recurrent cardiovascular event in patients with HIGH FcγRIIa.

Combining FcyRIIa with clinical risk scores may be very effective for identifying patients at high and low risk of subsequent CV events2-3.

illustration
Good estimate of CV risk in this subset of patients.
illustration
illustration
Much more effective stratification of patients between high and low risk.
the test
badge

FcyRIIa has three key advantages5 that will be validated in upcoming clinical studies for patients with acute coronary syndrome and chronic coronary artery disease.

FcyRlla Advantage

Low intra-individual variability over the course of a month, regardless of time of day.

Current platelet function tests demonstrate substantial
intra-individual variability.

FcyRlla Advantage

Predicts increased platelet reactivity in response to a variety of agonists.

Current platelet function tests measure platelet reactivity in response to a select agonist or group of agonists.

FcyRlla Advantage

Neither anticoagulants nor a P2Y12 antagonist alter platelet expression of FcyRIIa.

Current platelet function tests are very sensitive to assay conditions.

references

  1. Karas SP, et al. Blood 1982;60:1277-82.

  2. Schneider D, et al. J Am Coll Cardiol 2018;72:237-238.

  3. Schneider D, et al. Am J Cardiol 2020;125: 670-72.

  4. Yeh RW,et al, JAMA 2016;315: 1735–1749.

  5. McMahon SR, et al. Journal of Thrombosis and Thrombolysis (2019) 48:88–94.